| Literature DB >> 33219424 |
Vahid Shaygannejad1,2, Alireza Afshari-Safavi2,3, Boshra Hatef4.
Abstract
BACKGROUND: With the recent pandemic of the novel coronavirus disease (COVID-19), multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients for their compromised immune system have been in significant concern. Awareness and attitude about this virus have an important impact on infection prevention and coping with stress and anxiety. So we conducted this study to assess knowledge, attitude, and mental health status in MS and NMOSD patients within the COVID-19 pandemic.Entities:
Keywords: Attitude; Knowledge; Mental health; Multiple sclerosis; Neuromyelitis optica spectrum disorder; Novel coronavirus disease (COVID-19)
Mesh:
Year: 2020 PMID: 33219424 PMCID: PMC7678583 DOI: 10.1007/s10072-020-04905-5
Source DB: PubMed Journal: Neurol Sci ISSN: 1590-1874 Impact factor: 3.830
Participants’ demographic characteristics
| Variables | MS ( | NMOSD ( | Migraine ( | Control ( | |
|---|---|---|---|---|---|
| Sex; f, | 183 (82.1%) | 32 (78.0%) | 25 (86.2%) | 185 (75.5%) | 0.263 |
| Age, mean (SD) | 35.88 (7.49) | 34.09 (9.51) | 35.96 (727) | 34.20 (7.48) | 0.084 |
| Education; higher than diploma, | 158 (70.9%) | 21 (51.2%) | 20 (69.0%) | 154 (62.9%) | 0.059 |
| Marriage; married, | 165 (74.0%) | 30 (73.2%) | 24 (82.8%) | 162 (66.1%) | 0.121 |
| Disease duration, mean (SD) | 6.4 (5.2) | 3.78 (2.92) | NA | NA | 0.004 |
| Fist EDSS; median (IQR) | 2 (1) | NA | NA | NA | – |
| Current EDSS; median (IQR) | 0 (2) | NA | NA | NA | – |
| MS familial; y, | 36 (20.7) | NA | NA | NA | – |
| Physical comorbidity; y, | 64 (36.4) | NA | NA | NA | – |
| Psychological comorbidity; y, | 43 (24.4) | NA | NA | NA | – |
f female, y yes
Knowledge about COVID-19 among the study groups
| MS | NMOSD | Migraine | HC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Knowledge | Yes | No | I do not know | Yes | No | I do not know | Yes | No | I do not know | Yes | No | I do not know |
| Q1) Mask is effective in helping to prevent the spread of COVID-19 | 215 (96.4%) | 0 (0.0%) | 8 (3.6%) | 38 (92.7%) | 0 (0.0%) | 3 (73%) | 28 (96.6%) | 0 (0.0%) | 1 (3.4%) | 235 (95.9%) | 0 (0.0%) | 10 (4.1%) |
| Q2) Social distancing is effective in helping to prevent the spread of COVID-19 | 183 (82.1%) | 0 (0.0%) | 40 (17.9%) | 35 (85.4%) | 0 (0.0%) | 6 (14.6%) | 24 (82.8%) | 0 (0.0%) | 5 (17.2%) | 213 (86.9%) | 0 (0.0%) | 32 (131%) |
| Q3) Animals are most important source for spreading virus among humans | 89 (39.9) | 36 (16.1%) | 98 (43.9%) | 19 (46.3%) | 13 (31.7%) | 9 (22.0%) | 7 (24.1%) | 6 (20.7%) | 16 (55.2%) | 85 (34.7%) | 51 (20.8%) | 109 (44.5%) |
| Q4) Antibiotics can treat 2019-nCOV | 172 (77.1%) | 16 (7.2%) | 35 (15.7%) | 36 (87.8%) | 2 (4.9%) | 3 (7.3%) | 21 (72.4%) | 4 (13.8%) | 24 (13.8%) | 184 (75.1%) | 22 (9.0%) | 39 (15.9%) |
| Q5) Eating garlic helps prevent infection with 2019-nCOV | 104 (46.6%) | 67 (30.0%) | 52 (23.3%) | 20 (48.8%) | 11 (26.8%) | 10 (24.4%) | 11 (37.9%) | 9 (31.0%) | 9 (31.0%) | 110 (44.9%) | 75 (30.6%) | 60 (24.5%) |
| Q6) Eating sesame oil helps prevent infection with 2019-nCOV | 142 (63.7%) | 40 (17.9%) | 41 (18.4%) | 32 (78.0%) | 6 (14.6%) | 3 (7.3%) | 19 (65.5%) | 4 (13.8%) | 6 (20.7%) | 171 (69.8%) | 29 (11.8%) | 45 (18.4%) |
| Q7) Gargling with salt water or vinegar helps prevent infection with 2019-nCOV | 56 (25.1%) | 120 (53.8%) | 47 (21.1%) | 7 (17.1%) | 23 (56.1%) | 11 (26.8%) | 8 (27.6%) | 18 (62.1%) | 3 (10.3%) | 52 (21.2%) | 147 (60.0%) | 46 (18.8%) |
| Q8) Pneumonia vaccination helps prevent infection with 2019-nCOV | 156 (70.0%) | 21 (9.4%) | 46 (20.6%) | 33 (80.5%) | 1 (2.4%) | 7 (17.1%) | 22 (75.9%) | 2 (6.9%) | 5 (17.2%) | 175 (71.4%) | 28 (11.4%) | 42 (17.1%) |
| Q9) Electronic hand dryers helps prevent infection with 2019-nCOV | 95 (42.6%) | 100 (44.8%) | 28 (12.6%) | 16 (39.0%) | 17 (41.5%) | 8 (19.5%) | 13 (44.8%) | 12 (41.4%) | 4 (13.8%) | 98 (40.9%) | 110 (44.9%0 | 37 (15.1%) |
| Q10) 2019-nCOV can be excited in the food | 3 (1.3%) | 0 (0.0%) | 220 (98.7%) | 0 (0.0%) | 0 (0.0%) | 41 (100%) | 0 (0.0%) | 29 (100%) | 0 (0.0%) | 4 (1.6%) | 238 (97.1%) | 3 (1.2%) |
Attitude regarding COVID-19 among the study groups
| MS | NMOSD | Migraine | HC | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Attitude | Strongly agree | Agree | Disagree | Strongly disagree | Strongly agree | Agree | Disagree | Strongly disagree | Strongly agree | Agree | Disagree | Strongly disagree | Strongly agree | Agree | Disagree | Strongly disagree |
| Q1) Do you agree that COVID-19 is impossible to be controlled? | 78 (35.0%) | 64 (28.7%) | 3 (1.3%) | 78 (35.0%) | 0 (0.0%) | 0 (0.0%) | 2 (4.9%) | 39 (95.1%) | 9 (31.0%) | 13 (44.8%) | 0 (0.0%) | 7 (24.1%) | 98 (40.0%) | 77 (31.4%) | 3 (1.2%) | 67 (27.3%) |
| Q2) Do you agree that traveling within cities/country is safe? | 11 (4.9%) | 25 (11.3%) | 19 (8.5%) | 168 (75.3%) | 2 (4.9%) | 2 (4.9%) | 2 (4.9%) | 35 (85.4%) | 2 (6.9%) | 4 (13.8%) | 1 (3.4%) | 22 (75.9%) | 11 (4.5%) | 18 (7.3%) | 16 (6.5%) | 200 (81.7%) |
| Q3) Do you agree that proved vaccine will help to prevent the spread of new coronavirus? | 126 (56.5%) | 29 (13.0%) | 59 (26.5%) | 9 (4.0%) | 23 (56.1%) | 4 (9.8%) | 12 (29.3%) | 2 (4.9%) | 13 (44.8%) | 2 (6.9%) | 14 (48.3%) | 0 (0.0%) | 130 (53.1%) | 27 (11.0%) | 80 (32.7%) | 8 (3.3%) |
| Q5) Do you agree that avoiding contact with individuals with symptoms of COVID-19 can prevent spread of disease? | 88 (39.5%) | 96 (43.0%) | 28 (12.6%) | 11 (4.9%) | 19 (46.3%) | 14 (34.1%) | 7 (17.1%) | 1 (2.4%) | 7 (24.1%) | 7 (24.1%) | 8 (27.6%) | 7 (24.1%) | 102 (41.6%) | 113 (46.1%) | 29 (11.8%) | 1 (0.4%) |
| Q6) Do you agree that patients with COVID-19 should be isolated at an isolation hospital or home for a certain period of time? | 109 (48.9%) | 68 (30.5%) | 44 (19.7%) | 2 (0.9%) | 19 (46.3%) | 14 (34.1%) | 8 (19.5%) | 0 (0.0%) | 12 (41.4%) | 9 (31.0%) | 8 (27.6%) | 0 (0.0%) | 128 (52.2%) | 61 (24.9%) | 54 (22.0%) | 2 (0.8%) |
| Q4) Do you agree that most COVID-19 patients will be treated? | 149 (66.8) | 68 (30.5%) | 6 (2.7%) | 0 (0.0%) | 28 (68.3%) | 12 (29.3%) | 1 (2.45) | 0 (0.0%) | 21 (72.4%) | 2 (6.9%) | 4 (13.8%) | 2 (6.9%) | 180 (73.5%) | 56 (22.9%) | 9 (3.7%) | 0 (0.0%) |
| Q7) Do you agree that patients with COVID-19, who are declared cured should be isolated at home for a certain period of time? | 176 (78.9%) | 38 (17.0%) | 1 (0.4) | 8 (3.6%) | 39 (95.1%) | 2 (4.9%) | 0 (0.0%) | 0 (0.0%) | 23 (79.3%) | 3 (10.3%) | 0 (0.0%) | 3 (10.3%) | 198 (80.8%) | 34 (13.9%) | 1 (0.4%) | 12 (4.9%) |
Comparison of knowledge, attitude, and DASS score among the study groups
| MS | NMOSD | Migraine | HC | ||
|---|---|---|---|---|---|
| Depression | 14.62 (9.68) | 12.29 (8.37) | 17.00 (9.64) | 11.35 (8.71) | 0.054 |
| Anxiety | 16.34 (10.83) | 14.03 (10.06) | 17.89 (12.53) | 12.65 (9.64) | 0.080 |
| Stress | |||||
| Total DASS | |||||
| Attitude | 24.6 (2.0) | 24.87 (1.84) | 24.10 (2.22) | 24.57 (2.15) | 0.450 |
| Knowledge | 6.80 (1.58) | 6.23 (1.78) | 7.57 (1.39) | 6.32 (1.50) | 0.107 |
P < 0.05 is considered statistically significant
Descriptive overview of the questions regarding most common symptoms of COVID-19, source of receiving information about COVID-19, and major worries about it
| MS ( | NMOSD ( | Migraine (29) | HC ( | |
|---|---|---|---|---|
| Symptoms of COVID-19 | ||||
| Dyspnea | 196 (87.8%) | 34 (82.9%) | 24 (82.7%) | 178 (72.6%) |
| Fever | 189 (84.7%) | 31 (75.6%) | 23 (79.3%) | 176 (71.8%) |
| Dry cough | 185 (82.9%) | 28 (68.2%) | 24 (82.7%) | 163 (66.5%) |
| Muscle pain | 107 (47.9%) | 25 (61.0%) | 17 (58.6%) | 106 (43.2%) |
| Headache | 89 (39.9%) | 14 (34.1%) | 16 (55.1%) | 91 (37.1%) |
| Rhinorrhea | 56 (25.1%) | 12 (29.2%) | 10 (34.4%) | 50 (20.4%) |
| Diarrhea | 54 (24.2%) | 10 (24.3%) | 8 (27.5%) | 40 (16.3%) |
| Dizziness | 31 (13.9%) | 7 (17.0%) | 6 (20.6%) | 32 (13.0%) |
| Vomit | 32 (14.3%) | 8 (19.5%) | 7 (24.1%) | 38 (15.5%) |
| Weight loss | 10 (4.4%) | 1 (2.4%) | 0 (0.0%) | 3 (1.2%) |
| Sources of COVID-19 information | ||||
| Official media | 129 (57.8%) | 22 (53.6%) | 24 (82.7%) | 112 (45.7%) |
| Social media | 89 (39.9%) | 24 (58.5%) | 20 (68.9%) | 125 (51.0%) |
| Familial doctor | 65 (29.1%) | 7 (17.0%) | 10 (34.4%) | 47 (19.1%) |
| Others | 34 (15.2%) | 9 (21.9%) | 3 (10.3%) | 27 (11.0%) |
| Major worry regarding COVID-19 | ||||
| Worry for myself due to the compromised immune system | 133 (55.1%) | 34 (82.9%) | 5 (17.2%) | 18 (7.3%) |
| Worry for my close families | 84 (37.6%) | 18 (43.9%) | 29 (100.0%) | 179 (73.1%) |
| Worry for elderly persons | 100 (44.8%) | 8 (19.5%) | 18 (62.0%) | 27 (11.20%) |
| Others | 19 (8.5%) | 6 (14.6%) | 6 (20.6%) | 61 (24.9%) |
Results of logistic regression analysis of the association between demographic and clinical features and DASS score, knowledge, and attitude in MS patients
| Depression | Anxiety | Stress | Total | Attitude | Knowledge | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B (95% CI) | B (95% CI) | B (95% CI) | B (95% CI) | B (95% CI) | B (95% CI) | |||||||
| Sex (ref. = male) | 2.67 (− 1.69, 7.04) | 0.227 | 1.35 (− 3.55, 6.25) | 0.586 | 2.27 (− 2.24, 6.78) | 0.321 | 6.30 (− 7.19, 19.8) | 0.357 | 0.72 (− 0.41, 1.86) | 0.212 | 1.69 (− 1.26, 4.65) | 0.260 |
| Age | 0.02 (− 0.21, 0.24) | 0.880 | 0.02 (− 0.23, 0.28) | 0.856 | 0.02 (− 0.22, 0.25) | 0.870 | 0.06 (− 0.65, 0.77) | 0.865 | 0.02 (− 0.04, 0.08) | 0.499 | 0.04 (− 0.12, 0.20) | 0.627 |
| Disease duration | − 0.09 (−0.50, 0.31) | 0.649 | − 0.11 (− 0.57, 0.35) | 0.631 | − 0.03 (− 0.45, 0.40) | 0.894 | − 0.23 (− 1.51, 1.04) | 0.716 | 0.03 (− 0.06, 0.12) | 0.545 | − 0.08 (− 0.34, 0.17) | 0.519 |
| First EDSS | − 0.73 (− 2.38, 0.91) | 0.378 | − 0.65 (− 2.52, 1.21) | 0.489 | − 0.90 (− 2.62, 0.82) | 0.303 | − 2.29 (− 7.44, 2.86) | 0.380 | 0.14 (− 0.26, 0.54) | 0.498 | − 0.74 (− 1.83, 0.34) | 0.181 |
| Current EDSS | − 0.51 (− 1.76, 0.73) | 0.417 | − 0.44 (− 1.85, 0.96) | 0.533 | − 0.48 (− 1.79, 0.82) | 0.465 | − 1.44 (− 5.34, 2.46) | 0.465 | 0.05 (− 0.27, 0.37) | 0.770 | − 0.55 (− 1.42, 0.31) | 0.212 |
| MS familial (ref. = yes) | 1.16 (− 3.15, 5.48) | 0.594 | 1.92 (− 2.96, 6.80) | 0.437 | 1.88 (− 2.63, 6.40) | 0.411 | 4.97 (− 8.53, 18.4) | 0.468 | − 1.08 (− 2.29, 0.11) | 0.076 | 0.36 (− 2.94, 3.68) | 0.827 |
| 0.99 (− 2.95, 4.94) | 0.619 | − 0.57 (− 5.04, 3.90) | 0.800 | − 0.16 (− 4.31, 3.98) | 0.938 | 0.25 (− 12.13, 12.6) | 0.967 | 0.19 (− 2.75, 3.14) | 0.897 | |||
| 1.92 (− 1.76, 5.62) | 0.303 | 2.27 (− 1.91, 6.44) | 0.284 | 2.75 (− 1.08, 6.59) | 0.158 | 6.95 (− 4.57, 18.4) | 0.235 | 0.46 (− 0.55, 1.47) | 0.373 | − 0.85 (− 3.64, 1.92) | 0.545 | |
P < 0.05 is considered statistically significant